| Literature DB >> 31748742 |
Christina Ising1,2, Carmen Venegas1, Shuangshuang Zhang1,2, Hannah Scheiblich1,2, Susanne V Schmidt3, Ana Vieira-Saecker1,2, Stephanie Schwartz1,2, Shadi Albasset1,2, Róisín M McManus1,2, Dario Tejera2, Angelika Griep2, Francesco Santarelli2, Frederic Brosseron2, Sabine Opitz1,2, James Stunden4, Maximilian Merten1, Rakez Kayed5, Douglas T Golenbock6, David Blum7, Eicke Latz2,3,6, Luc Buée7, Michael T Heneka8,9,10.
Abstract
Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31748742 PMCID: PMC7324015 DOI: 10.1038/s41586-019-1769-z
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962